Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20471917 | 0.88 | EPHX2 (0.48) | EPHX2ADRA1APRMT1ALDH1A1LMNA | |
| SCHEMBL27134718 | 0.86 | LMNA (0.49) | EPHX2ALDH1A1LMNAHTTMAPK1 | |
| SCHEMBL27860861 | 0.84 | HDAC3 (0.47) | EPHX2ALDH1A1LMNA | |
| SCHEMBL8186241 | 0.83 | ACHE (0.56) | ALDH1A1LMNA | |
| SCHEMBL27357581 | 0.83 | EPHX1 (0.61) | — | |
| SCHEMBL31580499 | 0.81 | LMNA (0.47) | EPHX2ALDH1A1LMNAKMT2AHTT | |
| SCHEMBL9830057 | 0.81 | EPHX2 (0.60) | EPHX2ADRA1APRMT1KMT2AHTT | |
| SCHEMBL10141268 | 0.81 | ACHE (0.58) | EPHX2ALDH1A1LMNA | |
| SCHEMBL8193146 | 0.81 | ACHE (0.53) | ALDH1A1LMNAHTTMAPK1 | |
| SCHEMBL10119353 | 0.81 | LMNA (0.51) | ALDH1A1LMNAHTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187755-B2 | Minimal saponin analogues, synthesis and use thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220275017-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275017-A1 | MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF | DDOST, SI, STT3A | EPHX2 1541/4885ADRA1A 4429/4885PRMT1 3470/4885 |
| US-12187755-B2 | Minimal saponin analogues, synthesis and use thereof | DDOST, SI, STT3A | EPHX2 1541/4885ADRA1A 4429/4885PRMT1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.